Role of apoptotic regulators in human epithelial ovarian cancer

Cancer Biology and Therapy

Volumn 6, Issue 7, 2007, Pages 1101-1105

  Kar, Rajarshi ^a   Sen, Sudip ^a   Singh, Archna ^a   Sharma, Himani ^a   Kumar, Sunesh ^a   Gupta, Siddhartha Dutta ^a   Singh, Neeta ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Apoptotic index; Ascitic cells; Bcl 2 family; BRCA1; Ovarian cancer; Survivin; Telomerase activity

Indexed keywords

BRCA1 PROTEIN; K RAS PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SURVIVIN; TELOMERASE;

APOPTOSIS; ARTICLE; ASCITES CELL; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; GENE INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NICK END LABELING; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TISSUE SECTION; WESTERN BLOTTING;

EID: 42449158066     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.7.4329     Document Type: Article

References (23)

1. Crijns APJ, Duiker EW, DeJongy S, Willemsey PHB, Van Der Zee AGJ, de Vries EG. Molecular prognostic markers in ovarian cancer: Toward patient-tailored therapy. Int J Gynecol Cancer 2006; 16:152-165.
2. Davidson B, Risberg B, Reich R, Berner A. Effusion cytology in ovarian cancer: New molecular methods as aids to diagnosis and prognosis. Clin Lab Med 2003; 23:729-54.
3. Kmet M, Cook LS, Mangliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003; 97:389-404.
4. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002; 94:990-1000.
5. Varras MN, Sourvinos G, Diakomanolis E, Koumantakis E, Flouris GA, Lekka-Katsouli J, Michalas S, Spandidos DA. Detection and clinical correlations of ras gene mutations in human ovarian tumors. Oncology 1999; 56:89-96.
6. Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, Jedryka M, Goluda M, Chudecka-Glaz A, Rzepka-Gorska I, Klimek M, Urbanski K, Breborowicz J, Zielinski J, Markowska J. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 2003; 88:848-54.
7. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR. Expression of Bcl-xl in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96:287-95.
8. Cohen C, Christina M, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: Correlation with apoptotic markers and prognosis. Mod Pathol 2003; 16:574-83.
9. Ernst A, Okkels H, Grove A, Svarrer T, Knudsen A, Madsen PH, Krarup HB. Telomerase activity determined by conventional telomeric repeat amplification protocol and reverse transcriptase-polymerase chain reaction assay in ovarian lesions: A comparison of assays. Scand J Clin Lab Invest 2006; 66:287-97.
10. Dutta T, Sharma H, Kumar L, Dinda AK, Kumar S, Bhatla N, Singh N. Neoadjuvant chemotherapy for epithelial ovarian cancer-role of apoptosis. Cancer Chemother Pharmacol 2005; 56:427-35.
11. Singh A, Sharma H, Salhan S, Gupta SD, Bhatla N, Jain SK, Singh N. Evaluation of expression of apoptosis-related proteins and their correlation with HPV, telomerase activity, and apoptotic index in cervical cancer. Pathobiology 2004; 71:314-22.
12. Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol 2001; 20:64-78.
13. Wärnberg F, White D, Anderson E, Knox F, Clarke RB. Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res 2006; 8:R21.
14. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. K-ras mutations in nonmucinous ovarian epithelial tumors: A molecular analysis and clinicopathologic study of 144 patients. Cancer 1998; 82:1088-95.
15. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human Survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21:2613-22.
16. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002; 21:315-20.
17. Lu KH, Broaddus RR. Gynecological tumors in hereditary nonpolyposis colorectal cancer: We know they are common - now what? Gynecol Oncol 2001; 82:221-2.
18. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000; 156:409-17.
19. Taylor MRG. Genetic testing for inherited breast and ovarian cancer syndromes: Important concepts for the primary care physician. Postgrad Med J 2001; 77:11-5.
20. Berchuck A, Carney M. Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997; 54:541-4.
21. Diebold J, Baretton G, Felchner M, Meier W, Dopper K, et al. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996; 105:341-349.
22. Preethi TR, Chacko P, Kesari AL, Praseeda I, Chellam VG, Pillai MR. Apoptosis in epithelial ovarian tumors. Pathol Res Pract 2002; 198:273-80.
23. Sapi E, Okpokwasili NI, Rutherford T. Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients. Cancer Detect Prev 2002; 26:158-67.